Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target remains the same with $900.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co’s strong positioning in the pharmaceutical market. The company is preparing for the launch of Orforglipron, a promising treatment for type 2 diabetes and obesity, with a significant inventory build-up that indicates readiness to meet market demand. This preparation, coupled with an expected high gross margin, suggests substantial revenue potential for the product.
Additionally, Eli Lilly’s strategic decision to manufacture Orforglipron’s active pharmaceutical ingredient in the U.S. could mitigate risks related to tariffs, further strengthening its market position. The company’s robust pipeline, evidenced by recent approvals like donanemab, and its strong oncology franchise, are expected to contribute to sustained growth, supporting the overall positive outlook for the company’s financial performance.
In another report released on April 17, Morgan Stanley also maintained a Buy rating on the stock with a $1,124.00 price target.
Based on the recent corporate insider activity of 135 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.